Each enteric-coated tablet contains Diclofenac Sodium 50 mg + Serratiopeptidase 10 mg.

Tolpa-D is a combination of Diclofenac Sodium, a nonsteroidal anti-inflammatory drug (NSAID), and Serratiopeptidase, a proteolytic enzyme with anti-inflammatory and anti-edematous properties. The formulation provides effective relief from acute pain, inflammation, and swelling by combining potent prostaglandin inhibition with enzymatic reduction of inflammatory exudates and tissue edema. The enteric coating helps minimize gastric irritation by preventing drug release in the stomach.

Tolpa-D is indicated for the treatment of acute pain in adults, including pain associated with musculoskeletal injuries, postoperative conditions, dental procedures, and inflammatory disorders where pain and swelling require combined anti-inflammatory and analgesic therapy.

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that exerts anti-inflammatory, analgesic, and antipyretic effects by inhibiting cyclooxygenase (COX) enzymes and suppressing prostaglandin synthesis. Serratiopeptidase binds to alpha-2-macroglobulin in the circulation, masking its antigenicity while preserving enzymatic activity. It gradually accumulates at sites of inflammation, where it hydrolyses inflammatory mediators such as bradykinin, histamine, and serotonin, thereby reducing capillary permeability and tissue edema. It also promotes fibrinolytic activity by inhibiting plasmin inhibitors, facilitating the resolution of inflammatory exudates.

The recommended dosage is one tablet twice daily, preferably morning and evening after food, or as directed by the treating physician.

Tolpa-D is contraindicated in patients with known hypersensitivity to Diclofenac, Serratiopeptidase, or any component of the formulation, active peptic ulcer disease or gastrointestinal bleeding, pregnancy, history of anaphylactic reactions to NSAIDs, perioperative pain associated with coronary artery bypass graft (CABG) surgery, and in patients with severe renal or hepatic failure.